Media & Press

On July 23, 2026, we filed our first non-provisional patent application \u2014 a genuine milestone for ABENA IHR, and one that reflects years of clinical insight distilled into a defensible, foundational piece of intellectual property.

At the heart of this filing is a simple but overlooked idea: instead of guessing at a patient's endocannabinoid function through genetic proxies, ABENA IHR measures the endocannabinoid system directly. That distinction \u2014 direct biomarker measurement over indirect genetic prediction \u2014 is what allows our platform to deliver insights that are both more accurate and more clinically actionable, and it's the innovation this filing protects.

This filing builds on a series of earlier provisional applications and represents the next step in building a real, defensible moat around the science behind ABENA IHR \u2014 science grounded in integrative and cannabinoid medicine, and built to hold up to the same rigor as any conventional clinical system.

We're proud of this milestone, and even more excited about what it protects: a platform designed to bring integrative medicine the analytical rigor it has long deserved.